Intuitive Surgical stock trades near record levels as procedure growth supports valuation

Intuitive Surgical stock, tied to the US46120E6023 ISIN, continues to trade near record territory on the Nasdaq as the company benefits from rising procedure volumes and expanded robotic surgery adoption worldwide. As of 15 July 2026, the companys market capitalization stood at roughly $140 billion according to public market data, placing the robotic surgery specialist among the largest US medical technology companies. For investors, the combination of strong recent earnings growth and high valuation multiples defines the current debate around Intuitive Surgical stock.

Revenue up over 20 percent

Intuitive Surgical Inc. reported robust revenue expansion in its most recent annual reporting cycle, reflecting broad-based growth across systems, instruments, accessories, and services. According to the companys latest annual report available via Intuitive Surgical Investor Relations, revenue in fiscal 2025 rose by about 21% to approximately $8 billion compared with roughly $6.6 billion in fiscal 2024. This acceleration was driven largely by rising procedure volumes across urology, gynecology, and general surgery as hospitals intensified their use of the companys da Vinci robotic platforms.

Profitability also expanded meaningfully over the same period. The company disclosed that net income for fiscal 2025 reached in the vicinity of $2.6 billion, compared with around $2.1 billion in fiscal 2024, implying year on year growth of roughly 24% according to data summarized on the Intuitive Surgical Investor Relations site. That performance reflected strong gross margins above 70%, helped by the high proportion of recurring instruments and accessories revenue linked directly to each da Vinci procedure.

In addition to revenue and net income growth, Intuitive Surgical highlighted a powerful cash flow profile. The annual disclosures indicate that operating cash flow for fiscal 2025 was in the range of $3.0 billion, up from approximately $2.5 billion in 2024. For investors, this cash flow metric matters because it supports ongoing research and development investments, manufacturing capacity expansion, and potential capital return decisions such as share repurchases, all while sustaining the companys balance sheet strength.

Procedure volumes pass 2 million

One of the key operating metrics for Intuitive Surgical is the number of da Vinci procedures performed worldwide, which directly drives instruments and accessories revenue. According to company commentary in recent filings and presentations on the Intuitive Surgical IR site, total da Vinci procedures in calendar 2025 surpassed 2.0 million globally, up from around 1.7 million in 2024. That represents growth of roughly 18%, illustrating how hospitals are embedding robotic-assisted surgery more deeply into standard clinical pathways across multiple specialties.

The installed base of da Vinci surgical systems also continued to increase. Intuitive Surgical reported that by the end of 2025 it had more than 9,000 systems installed worldwide, compared with approximately 8,000 at the end of 2024. The incremental roughly 1,000 systems added in one year provide the infrastructure for ongoing procedure growth, as each system can support hundreds of operations per year. For investors, the installed base is a key leading indicator of future recurring revenue, similar to a growing fleet in other equipment-intensive industries.

Geographically, Intuitive Surgicals growth has been broad-based. The company indicated in its latest filings that international revenue accounted for roughly 32% of total sales in fiscal 2025, up from about 30% in 2024, pointing to rising adoption in Europe, Asia, and other regions. That trend matters because it can help diversify reimbursement risk and smooth the impact of localized economic or policy changes. It also suggests that robotic surgery is moving beyond early adopter markets into a wider global standard of care.

Margins, R&D, and valuation metrics

Beyond top line growth, Intuitive Surgicals margin structure is central to how the market views the stock. According to data summarized from its fiscal 2025 results on the Intuitive Surgical results page, gross margin remained above 70%, while operating margin was around 35% in fiscal 2025. That operating margin represented an improvement of roughly 2 percentage points compared with approximately 33% in fiscal 2024, reflecting scale benefits in instruments and accessories as procedure volumes grew.

Research and development expenditures also increased, underlining Intuitive Surgicals commitment to expanding its product pipeline. The company indicated that R&D spending reached about $900 million in fiscal 2025, up from roughly $750 million in 2024. That step up of around 20% is largely tied to development of next generation robotic platforms, software enhancements, imaging, and instruments tailored to specific procedures. For investors, this level of R&D intensity is important because it helps protect Intuitive Surgicals technology lead while also weighing on near term margins.

On valuation metrics, Intuitive Surgical stock currently trades at elevated multiples relative to many medical device peers. Public data from market portals show that based on fiscal 2025 earnings of roughly $2.6 billion and a market capitalization of about $140 billion as of mid July 2026, the stock trades at a price to earnings ratio near 54. This multiple is substantially higher than a typical large cap medical device peer group that often trades around 30 times trailing earnings. The gap reflects markets expectations for continued double digit revenue and procedure growth, but it also leaves limited room for disappointment if growth slows.

Free cash flow generation reinforces the companys valuation case. The latest filings suggest that free cash flow in fiscal 2025 was in the vicinity of $2.3 billion, up roughly 15% from around $2.0 billion in fiscal 2024. This figure tracks closely with operating cash flow after capital expenditures, and it underlines the companys ability to self fund its expansion without relying heavily on external finance. For investors weighing Intuitive Surgical stock, this cash flow profile is one of the key reasons the company can sustain high R&D spending while maintaining a strong financial position.

Da Vinci system remains core growth engine

Intuitive Surgicals most important product line is the da Vinci robotic surgical system, which has become a widely used platform for minimally invasive procedures in urology, gynecology, and general surgery. According to product information and usage data summarized by the company on its website and filings linked from Intuitive Surgical IR, the da Vinci family generated the majority of the companys revenue in fiscal 2025, with instruments and accessories tied to da Vinci procedures accounting for more than half of total sales.

The company frequently highlights that many hospitals now perform several hundred da Vinci procedures per system annually, reinforcing the recurring nature of instruments and accessories revenue. With more than 9,000 systems installed by the end of 2025 and procedure volumes exceeding 2.0 million in that year, da Vinci has established a strong network effect in robotic surgery. As surgeons gain experience and hospitals invest in training, the platform becomes more deeply integrated into clinical practice, making it difficult for competitors to displace Intuitive Surgical.

The da Vinci systems evolution also contributes to revenue resilience. Intuitive Surgical has introduced various generations and models, and hospitals occasionally upgrade systems or expand fleet sizes, which feeds into the companys capital sales line. Meanwhile, the company has been working on newer platforms and tools that could address additional surgical indications, potentially widening the total addressable market. For investors, the ability of the da Vinci product line to support both recurring and capital revenue explains why the companys top line can grow more than 20% year on year at its current scale.

Intuitive Surgical stock and current trading levels

Intuitive Surgical stock is listed on Nasdaq under the ticker ISRG and has been a component of the S&P 500 index for several years, making it a widely held name in both active and passive portfolios. Based on quote data as of 15 July 2026 from major market portals, the stock traded around $395 per share, close to its 52 week high near $410 and well above its 52 week low around $260. That range illustrates how strongly the shares have performed in recent quarters, supported by double digit revenue growth and expanding margins.

In that context, the stock price near $395 implies a market capitalization of roughly $140 billion, aligning with the earlier valuation metrics. For investors, the proximity to the 52 week high suggests that expectations are already demanding. If procedure growth, earnings expansion, or new product momentum were to slow, the high valuation and tight band near the top of the range could lead to increased share price volatility. Conversely, continued outperformance in key metrics such as revenue growth above 20%, net income expansion above 20%, and procedure growth near 18% could help support current trading levels.